ArticleAmerican journal of preventive cardiology2025
Advanced biologic therapies and cardiovascular events in patients with inflammatory bowel disease.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunomodulators, Biologics, and 5-ASA for Inflammatory Bowel Disease and Major Adverse Cardiovascular Events in Older Adults.JAMA network open · 2026Article
- Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Atherosclerotic cardiovascular disease (ASCVD) risk is increased in patients with Inflammatory Bowel Disease (IBD). The impact of advanced biologic therapies (ABT) on ASCVD risk in patients with IBD has not been reported. This study tests the hypothesis of a protective effect of immune modulation with ABT on ASCVD risk in patients with IBD. Methods: Retrospective cohort study using the TriNetX Network. Results: This analysis included 72,650 individuals in each of two matched cohorts with IBD: one receiving ABT and one receiving non-ABT (NABT). The probabilities of experiencing an ischemic cardiovascular, cerebrovascular, or peripheral vascular event were all significantly lower in the ABT group, than in the NABT group. The probabilities of any ASCVD event at one, three, and five years in the ABT group were also lower than in the NABT group (8.3 % vs. 11.9 %, OR 0.67; 13.0 % vs. 17.9 %, OR 0.69; and 15.0 % vs. 21.2 %, OR 0.68; respectively, all Conclusions: ABT were associated with significantly fewer ASCVD events than NABT in the IBD patient population. Among drug subclasses, interleukin 12/23 inhibitors were associated with the strongest benefit. Future prospective, randomized studies examining the efficacy and safety as well as the differential benefit of drug subclasses on ASCVD outcomes and mechanisms responsible for the ABT benefit are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.